[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353939-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353939-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prophylactic-hpv-vaccination-in-gynaecological-practice-recommendations-practices-and-challenges-reported-in-the-esgo-perch-hpv-survey","Prophylactic HPV Vaccination in Gynaecological Practice - Recommendations, Practices, and Challenges Reported in the ESGO-PERCH HPV Survey","","HPV vaccination prevents HPV-related cancers when given before viral exposure, yet vaccination approaches for patients who already have gynaecological cancers are poorly described. An international, web-based ESGO/ENYGO survey assessed clinicians’ attitudes, practices, and perceived barriers across scenarios and age groups. Among 149 respondents from 33 countries, most supported vaccination after cervical precancer and a majority for invasive cervical cancer, while support was lower for endometrial and ovarian cancer. Reported barriers included misinformation, missing education materials, and time constraints. The survey highlights practice-evidence gaps and the need for clearer, evidence-based guidance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prophylactic-hpv-vaccination-in-gynaecological-practice-recommendations-practices-and-challenges-reported-in-the-esgo-perch-hpv-survey/353939/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prophylactic-hpv-vaccination-in-gynaecological-practice-recommendations-practices-and-challenges-reported-in-the-esgo-perch-hpv-survey/353939.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the focus of the ESGO-PERCH HPV survey?","Question",{"text":63,"@type":64},"The survey evaluated clinicians’ attitudes, practices, and perceived barriers to HPV vaccination for patients with gynaecological cancer or pre-invasive disease across multiple scenarios and age groups.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did clinicians’ support for HPV vaccination vary by cancer type and patient age?",{"text":68,"@type":64},"Most clinicians supported vaccination for cervical precancer, with lower endorsement for invasive cervical cancer, and even lower support for endometrial and ovarian cancer, varying from 16% to 53% depending on age.",{"name":70,"@type":61,"acceptedAnswer":71},"What barriers discouraged clinicians from recommending HPV vaccination?",{"text":72,"@type":64},"Key barriers included misinformation, lack of patient education materials, and time constraints, along with economic factors and uncertainty about efficacy in oncologic settings.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353939,1790154973,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Article  \nProphylactic HPV Vaccination in Gynaecological Practice: Recommendations, Practices, and Challenges Reported in the ESGO-PERCH HPV Survey  \nJoanna Kacperczyk-Bartnik 1,2, *, Marc Arbyn 3,4, Sophie Denoël 3, Esra Bilir 5,6,7, Nina Dhollander 3,  \nZoia Razumova 8, Khayal Gasimli 9,10, Andrej Cokan 11,12, Houssein El Hajj 13, Tibor Andrea Zwimpfer 14,15,16, Maria Kyrgiou 17,18, Murat Gultekin 19 and Nicolò Bizzarri 20  \nAcademic Editor: Francesco Vitale  \nReceived: 21 January 2026  \nRevised: 9 March 2026  \nAccepted: 13 March 2026  \nPublished: 16 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Gynaecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland  \n2 II Department of Obstetrics, Gynaecology and Gynaecological Oncology, Medical University of Warsaw, 00-315 Warsaw, Poland  \n3 Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, 1050 Brussels, Belgium  \n4 Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, 9000 Ghent, Belgium  \n5 Department of Gynecologic Oncology, Koç University School of Medicine Department,  \n34450 Istanbul, Türkiye  \n6 School of Medicine, American University of Sovereign Nations, Sacaton, AZ 85147, USA  \n7 Department of Gynecology and Obstetrics, University Medical Center Goettingen,  \n37075 Goettingen, Germany  \n8 Women’s and Children’s Health, Karolinska Institute, 171 77 Stockholm, Sweden  \n9 Department of Gynecology and Obstetrics, J. W. Goethe University Hospital, 60590 Frankfurt, Germany  \n10 Department of Gynecology and Obstetrics, Hospital zum Heiligen Geist, 60311 Frankfurt, Germany  \n11 Department of Gynaecological and Breast Oncology, University Medical Centre Maribor, 2000 Maribor, Slovenia  \n12 Medical Faculty Maribor, University of Maribor, 2000 Maribor, Slovenia  \n13 Gynaecologic Oncology Department, Gustave Roussy, 94800 Villejuif, France  \n14 Gynaecological Cancer Centre, University Hospital Basel, 4031 Basel, Switzerland  \n15 Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia  \n16 Department of Biomedicine, University of Basel, 4031 Basel, Switzerland  \n17 Department of Metabolism, Digestion & Reproduction-Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 0NN, UK  \n18 West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust, London W2 1NY, UK  \n19 Department of Obstetrics and Gynecology, Faculty of Medicine, Hacettepe University, 06230 Ankara, Türkiye  \n20 UOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e Del Bambino e della Sanità Pubblica, Fondazione Policlinico Universitario a. Gemelli, IRCCS, 00168 Rome, Italy  \n* [Correspondence: joanna.kacperczyk-bartnik@nio.gov.pl](Correspondence: joanna.kacperczyk-bartnik@nio.gov.pl)  \nAbstract  \nBackground/Objectives: HPV vaccination is highly effective in preventing HPV-related cancers when administered before viral exposure. However, vaccination practices for patients already diagnosed with gynaecological cancers remain poorly characterized. Understanding clinicians’ perspectives and barriers is essential for optimizing preventive strategies in oncologic care. Methods: We conducted an international, web-based survey among members of the European Society of Gynaecological Oncology (ESGO) and the European Network of Young Gynaecological Oncologists (ENYGO) . The questionnaire explored clinicians’ attitudes, practices, and perceived obstacles regarding HPV vaccination in patients with gynaecological cancer or pre-invasive disease across multiple clinical scenarios and age groups. Results: A total of 149 respondents from 33 countries completed the survey. Most clinicians supported HPV vaccination for patients treated for cervical precancer (78–82% for patients under 45 ","cbCaiuRgkH71Z105","https://ap.wps.com/l/cbCaiuRgkH71Z105","pdf",1794133,13,"English","# Abstract\n# 1. Introduction\n# Abstract Background/Objectives\n# Abstract Methods\n# Abstract Results\n# Abstract Conclusions","[{\"question\":\"What was the focus of the ESGO-PERCH HPV survey?\",\"answer\":\"The survey evaluated clinicians’ attitudes, practices, and perceived barriers to HPV vaccination for patients with gynaecological cancer or pre-invasive disease across multiple scenarios and age groups.\"},{\"question\":\"How did clinicians’ support for HPV vaccination vary by cancer type and patient age?\",\"answer\":\"Most clinicians supported vaccination for cervical precancer, with lower endorsement for invasive cervical cancer, and even lower support for endometrial and ovarian cancer, varying from 16% to 53% depending on age.\"},{\"question\":\"What barriers discouraged clinicians from recommending HPV vaccination?\",\"answer\":\"Key barriers included misinformation, lack of patient education materials, and time constraints, along with economic factors and uncertainty about efficacy in oncologic settings.\"}]","Prophylactic HPV Vaccination in Gynaecological Practice - Recommendations, Practices, and Challenges Reported in the ESGO-PERCH HPV Survey | PDF",1790108069,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4034a0caf236e9806141ee3b9af4062.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dcd77ed221acedf1ec5249f94a88003.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/532ab3aa555b56cfe2b2e6bcfa84c41d.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/442941061a71f212fca4a6bcd07829e0.webp",980,1385]